Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Sells $47,784.00 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 3,982 shares of Alphatec stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $12.00, for a total value of $47,784.00. Following the transaction, the chief operating officer owned 744,936 shares in the company, valued at $8,939,232. This represents a 0.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Scott Lish also recently made the following trade(s):

• On Friday, June 13th, Scott Lish sold 22,727 shares of Alphatec stock. The shares were sold at an average price of $11.07, for a total value of $251,587.89.
• On Monday, May 19th, Scott Lish sold 55,375 shares of Alphatec stock. The shares were sold at an average price of $13.00, for a total value of $719,875.00.
• On Monday, May 5th, Scott Lish sold 12,000 shares of Alphatec stock. The shares were sold at an average price of $12.12, for a total value of $145,440.00.

Alphatec Price Performance

Shares of ATEC traded down $0.06 during trading hours on Tuesday, hitting $10.85. The stock had a trading volume of 233,597 shares, compared to its average volume of 2,064,924. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $13.14. The firm has a market capitalization of $1.59 billion, a P/E ratio of -9.43 and a beta of 1.05. The firm has a 50 day simple moving average of $11.87 and a 200-day simple moving average of $11.04.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 25.77%. The firm had revenue of $169.18 million for the quarter, compared to the consensus estimate of $167.57 million. During the same period in the prior year, the business earned ($0.34) EPS. Alphatec's quarterly revenue was up 22.2% compared to the same quarter last year. Equities analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price target for the company in a research report on Monday, June 16th. Needham & Company LLC reaffirmed a "buy" rating and issued a $16.00 price target on shares of Alphatec in a research report on Friday, May 2nd. Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 price target (up previously from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research report on Monday, April 14th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.89.

Institutional Investors Weigh In On Alphatec

A number of hedge funds have recently modified their holdings of ATEC. Bank of New York Mellon Corp raised its stake in shares of Alphatec by 119.3% during the 4th quarter. Bank of New York Mellon Corp now owns 662,239 shares of the medical technology company's stock valued at $6,079,000 after purchasing an additional 360,258 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Alphatec by 2.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 846,224 shares of the medical technology company's stock valued at $7,768,000 after purchasing an additional 23,002 shares in the last quarter. Atria Investments Inc grew its position in shares of Alphatec by 20.3% during the 4th quarter. Atria Investments Inc now owns 23,585 shares of the medical technology company's stock valued at $217,000 after purchasing an additional 3,976 shares in the last quarter. M&T Bank Corp purchased a new position in shares of Alphatec during the 4th quarter valued at $170,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Alphatec during the 4th quarter valued at $358,000. Institutional investors own 66.35% of the company's stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.